Option chain shows key data for Finch Therapeutics Gr's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Finch Therapeutics Gr.

Finch Therapeutics Gr (OTC:FNCH) Stock, Option Chain

Finch Therapeutics Gr

Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical date from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).

Stock Market

AMST

APDN

ATXI

BNAI

CSSE

New Oriental Education & Technology Group

ENPH

FNCH

GCTK

HELE

ISUN

LICN

MANH

MRSN

MULN

NIVF

NVTS

ODFL

RBBN

RCON

RILY

SNBR

TROO

TSLA

VAXX

VICR

WIMI

Connexa Sports Technologies Inc. - Common Stock

YYAI

Why Teledyne Technologies Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADPT

ADSK

ALXO

ASML

AWIN

CGEM

CHRO

CXAI

DFLI

DXYZ

DYNT

EDBL

EZGO

FWRD

HUBC

IBKR

INVO

JBHT

LGVN

MSTR

OTRK

PLCE

PRTG

RANI

SAGE

SBFM

SINT

SMXT

SNDL

SPEC

SXTC

TCON

TPET

VIAO

VIRX

VNDA

WISA

Shares of  The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings.

Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

ACAD

AEVA

ASAN

ASRT

BCAN

BLDE

The Beachbody Company, Inc. Class A Common Stock

BODI

BWMN

CLRO

CRBU

CTMX

DTSS

ESGL

GERN

GOEV

HRTG

IONM

JANX

JFBR

KITT

LEXX

LGCL

LICY

MNSO

NRXP

NUKK

OCUL

ONON

ORCL

PACK

PRST

RERE

RGLS

RNLX

SGLY

SPPL

TALK

VINC

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.

Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

FINCH THERAPEUTCS GRP INC by Finch Therapeutics Group, Inc.

Finch Therapeutics Group Inc

FINEOS Corp Holdings PLC Chess Depository Interest

FINEOS Corp Holdings PLC

PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) has outperformed the market over the past 5 years by 10.01% on an annualized basis producing an average annual return of 23.27%. Currently, PDD Holdings has a market capitalization of $144.22 billion. 
Buying $1000 In PDD: If an investor had bought $1000 of PDD stock 5 years ago, it would be worth $2,789.23 today based on a price of $103.85 for PDD at the time of writing.
<h3>PDD Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737503109_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Citigourp Global Markets 2% Protected Notes Linked To The Djia

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

As the oldest members of <a href="https://www.benzinga.com/personal-finance/24/12/42325436/despite-having-the-highest-income-gen-x-also-carries-the-most-debt-explaining-their-rock-bottom-consumer-sentiment">Generation X</a> (those born between 1965 and 1980) approach retirement, financial experts warn that many in this group may not be as prepared as they think. Generation X faces unique challenges as they prepare for retired life, from shortfalls in savings to unexpected costs that may arise.&nbsp;
Here's what experts say Gen Xers need to know to avoid these key pitfalls and ensure a more <a href="https://www.benzinga.com/personal-finance/24/11/41918104/are-you-on-track-to-retire-rich-heres-the-nest-egg-you-need-to-be-considered-a-wealthy-retiree">secure retirement</a>.&nbsp;
<h2 class="wp-block-heading">Look At Your Savings Goals</h2>
Many Gen Xers are significantly behind in their retirement savings. A recent study by Northwestern Mutual found that only 7% of Gen X respondents have saved more than 10 times their annual income–the amount most experts recommend for a comfortable retirement.&nbsp;
Don't Miss:
<ul>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>The average 401(k) balance soars to a record-breaking high – <a href="https://www.benzinga.com/money/average-401k-balances-soars-to-record-high">but what&#8217;s driving it?</a></li>
</ul>
Perhaps even more concerning, over half of Gen X respondents say they have only saved three times their annual income or less. Fidelity recommends having at least three times your annual salary by age 40, six times your salary by age 50 and eight times your salary by age 60 to stay on track for a comfortable retirement.&nbsp;
This shortfall in savings is compounded by the fact that many Gen Xers do not have a <a href="https://www.benzinga.com/personal-finance/financial-advisors/24/11/41702991/americans-worried-theyll-mess-up-retirement-income-planning-almost-half-fear-">retirement income plan</a>. According to Allianz, only 30% of Gen Xers have mapped out how they will fund their post-work years, the lowest rate among all generations surveyed.
<h2 class="wp-block-heading">Taxes and Healthcare Expenses</h2>
A common misconception among Americans is that taxes decrease in retirement. However, financial experts caution that many Gen Xers could face higher-than-expected tax burdens. The reason? Most have their retirement savings in tax-deferred accounts, like <a href="https://www.benzinga.com/personal-finance/24/11/42154984/new-findings-show-iras-and-401ks-contribute-less-than-20-of-retirees-income">401(k)s and IRAs</a>, which require taxes to be paid upon withdrawal.&nbsp;
"The big problem is that a lot of them are going to be faced with a lot of taxes in retirement," Jonathan Dane, founder and chief investment officer for Defiant Capital Group in Pittsburgh, told U.S. News. He says one way to mitigate this is to stop putting money in tax-deferred accounts and transition to Roth accounts, which allow for tax-free withdrawals.
See Also: The Biggest Disruption to IP since Disney — <a href="https://www.benzinga.com/money/elf-labs-1">Get in now as they monetize a $2 Trillion market by building content around the most profitable Character IP in history and combining it with the Patented Technology IP of the future.</a>
Another concern is healthcare costs. While Medicare provides comprehensive coverage starting at age 65, it doesn't cover everything. Long-term care expenses, like assisted living, typically aren't included. Experts suggest considering long-term care insurance or using a health savings account (HSA) to prepare for these costs.&nbsp;
<h2 class="wp-block-heading">Budgeting and Withdrawal Strategies</h2>
Financial planners warn that many Gen Xers don't clearly understand their spending habits. "They've been getting a paycheck for the last 40 years and they just don't know what they spend," Zach Ungerott of Hightower Wealth Advisors told U.S. News.
Knowing when and how much to withdraw from savings can make a significant difference. Starting withdrawals at age 59 ½ allows penalty-free access to funds in tax-advantaged accounts, but withdrawing too much too quickly risks prematurely depleting savings.
Trending: Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a>
<h2 class="wp-block-heading">Updating Estate Plans and Investments</h2>
Many Gen Xers have outdated estate plans that don't reflect their current wishes. Reviewing and updating wills, beneficiary designations and other documents is essential to ensure assets are distributed as intended.
Investment strategies may also need adjustment. While Gen X has benefited from stock market gains, experts suggest diversifying into more stable assets like bonds or annuities to protect against market downturns.
With retirement on the horizon, Generation X has limited time to close savings gaps, reassess strategies and prepare for potential obstacles. Working with a <a href="https://www.benzinga.com/money/best-online-financial-advisors">financial professional</a> can help this generation create a plan tailored to their needs, ensuring they are better positioned for a secure retirement.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/planning-your-retirement-new-changes-to-social-security-in-2025-could-affect-you">Planning Your Retirement? New Changes To Social Security In 2025 Could Affect You</a></li>
<li><a href="https://www.benzinga.com/money/suze-orman-retirement-bucket">&#8216;Which Bucket Do I Draw From First?&#8217; Suze Orman Explains To 67-Year-Old The Best Order For Tapping Into Her Retirement Accounts</a></li>
</ul>

Personal Finance

'It Won't Be Enough': Financial Experts Warn Gen X About Key Retirement Pitfalls

Fortinet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) has outperformed the market over the past 5 years by 20.28% on an annualized basis producing an average annual return of 33.54%. Currently, Fortinet has a market capitalization of $74.35 billion. 
Buying $100 In FTNT: If an investor had bought $100 of FTNT stock 5 years ago, it would be worth $411.90 today based on a price of $97.00 for FTNT at the time of writing.
<h3>Fortinet's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737502210_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FTNT

$100 Invested In Fortinet 5 Years Ago Would Be Worth This Much Today

According to the latest data from the Centers for Disease Control and Prevention, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus. The virus was confirmed on Friday at a commercial poultry production facility in Georgia, the nation's top state <a href="https://www.benzinga.com/general/biotech/25/01/43046294/bird-flu-raising-red-flags-among-health-officials-cdc-urges-faster-testing">for chicken production. </a>
What To Know: The CDC said that the current public health risk is low and the agency is watching the situation carefully and monitoring people with animal exposures. Bird flu is "widespread in wild birds worldwide and is causing outbreaks in poultry and U.S. dairy cows with several recent human cases in U.S. dairy and poultry workers," the CDC stated in its <a href="https://www.cdc.gov/bird-flu/situation-summary/index.html">most recent</a> update.&nbsp;
On Friday, the Georgia Department of Agriculture announced it <a href="https://agr.georgia.gov/avian-influenza">detected</a> a case of Highly Pathogenic Avian Influenza at a commercial poultry producer in the state. The case marks the first in Georgia, the nation's top state for chicken production, since the 2022 countrywide outbreak. 
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/01/43106379/trump-reverses-bidens-ai-policies-on-day-1-what-it-means-for-tech-giants-nvidia-amd-alphabet">Trump Reverses Biden&#8217;s AI Policies On Day 1: What It Means For Tech Giants Nvidia, AMD, Alphabet&nbsp;</a>
"This is a serious threat to Georgia's #1 industry and the livelihoods of thousands of Georgians who make their living in our state's poultry industry," Georgia Agriculture Commissioner Tyler Harper said in a news release.&nbsp;
According to an AP News<a href="https://apnews.com/article/bird-flu-georgia-chicken-commercial-flock-a5bcad4662d4cf60212f6acb4a55d2ad"> report,</a> the bird flu virus has been detected in 84 commercial and backyard flocks in the past month with 10.7 million birds affected. The virus has also been confirmed in dozens of dairy farms.
What Else: On Friday, Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) announced <a href="https://www.benzinga.com/general/biotech/25/01/43105845/why-is-moderna-stock-trading-higher-on-tuesday-2">it received</a> an additional $590 million award from the U.S. Department of Health and Human Services (HHS) to accelerate the development of its mRNA-based influenza vaccines, including bird flu.
In 2023, Moderna commenced a Phase 1/2 study to generate safety and immunogenicity data for an investigational pandemic influenza vaccine (mRNA-1018) candidate against the H5 and H7 avian influenza viruses. Based on the preliminary data from the Phase 1/2 study, Moderna is preparing to advance mRNA-1018 into Phase 3. 
Other pharmaceutical companies, including Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>), have bird flu vaccine candidates currently in clinical trials. 
CureVac BV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) started a phase I/II study on its bird flu vaccine candidate developed in collaboration with GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>). 
Egg producer Cal-Maine Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NYSE">CALM</a>) reported<a href="https://www.benzinga.com/news/earnings/25/01/42862269/cal-maine-foods-stock-climbs-after-strong-q2-results-eps-beat-revenues-beat"> its most recent </a>quarterly revenue of $954.7 million, well above the  $751.49 million consensus estimate, due in part to restricted supply resulting from highly pathogenic avian influenza (HPAI) outbreaks. Cal-Maine Foods stock gained more than 75% over the past six months. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/initiation/25/01/43102452/roku-analyst-sees-25-upside-as-tv-ad-dollars-go-digital">Roku Analyst Sees 25% Upside As TV Ad Dollars Go Digital&nbsp;</a></li>
</ul>
Photo: Shutterstock

Biotech

Equities

Government

General

CALM

CVAC

MRNA

NVAX

Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine

Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) has outperformed the market over the past 15 years by 11.59% on an annualized basis producing an average annual return of 23.61%. Currently, Super Micro Computer has a market capitalization of $19.00 billion. 
Buying $100 In SMCI: If an investor had bought $100 of SMCI stock 15 years ago, it would be worth $2,795.00 today based on a price of $32.45 for SMCI at the time of writing.
<h3>Super Micro Computer's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737501309_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SMCI

Here's How Much $100 Invested In Super Micro Computer 15 Years Ago Would Be Worth Today

An executive order signed by President Donald Trump put an emphasis on ending electric vehicle plans put in place by former President Joe Biden and could put an end to the $7,500 tax credits that helped <a href="https://www.benzinga.com/electric-vehicles">boost the sector.</a>
What Happened: One of Trump's first tasks since becoming president <a href="https://www.benzinga.com/tech/25/01/43090016/here-are-the-evs-which-could-lose-7500-ev-tax-credit-under-trump-administration">was to sign </a>the "Unleashing American Energy" executive order.
Trump's order says he is eliminating the "electric vehicle mandate" and also terminating the Green New Deal.
While Trump may need additional approval to end the $7,500 tax credit American consumers can currently get for buying numerous electric vehicle models, including several from Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), the order pauses the disbursement of funds that were part of the Inflation Reduction Act of 2022.
The electric vehicle tax credits have helped boost sales of EVs over the past several years, including Tesla. Once a beneficiary of tax credits for his company, Tesla CEO Elon Musk has changed his tune about the credits in recent years.
Musk <a href="https://www.benzinga.com/news/24/07/39934750/trump-presidency-and-ira-cut-would-be-devastating-for-competitors-says-elon-musk-long-term-probably">said recently</a> that he was okay with the tax credits going away and has pledged his support to Trump, who he supported during the 2024 presidential election.
In a quarterly earnings call in July 2024, Musk said Trump winning the election and the end of the tax credits could be "devastating" for Tesla rivals, but would likely end up being a long-term positive for his company. &nbsp;
"Long term probably actually helps Tesla, would be my guess, yes," Musk said at the time.
With the potential of the EV tax credits going away, Tesla influencer Sawyer Merritt conducted a poll on social media platform X to see if people thought the move would help or hurt Tesla.
"Long-term is the U.S. EV credit disappearing bullish, bearish, or neutral for Tesla," Merritt asked.
Here are the poll <a href="https://x.com/SawyerMerritt/status/1881777072017649722">results</a>, based on 16,294 votes.
<ul>
<li>Bullish: 40.4%</li>
<li>Neutral: 27.5%</li>
<li>Bearish: 19.4%</li>
<li>See Results: 12.6%</li>
</ul>
The largest percentage of voters believe the EV tax credit going away would be bullish for Tesla. This is likely related to the belief that the move would be bad for most EV companies, but hurt Tesla's competitors more. Tesla has profitability per vehicle and vertical integration for manufacturing, which helps the company on costs and scale.
When asked for his opinion, Merritt said he was neutral on the potential change.
"Hard to argue that it's really bullish since Tesla is currently the largest beneficiary of the EV credit, but it disappearing I don't think will be a negative as some are suggesting. Tesla is no doubt in the strongest position to withstand the impact of it disappearing vs their legacy auto competition," Merritt said.
Read Also: <a href="https://www.benzinga.com/news/global/25/01/43088582/gary-black-questions-elon-musks-take-on-ev-credit-removal-after-tesla-sales-drop-in-europe-not-sure-how-the-math-works">Gary Black Questions Elon Musk&#8217;s Take On EV Credit Removal After Tesla Sales Drop In Europe: &#8216;Not Sure How The Math Works&#8217;</a>
Why It's Important: Musk's stance on being against tax credits that help boost the market share of electric vehicle companies could be a surprise to many given his past support for the sector.
"Since the company's inception in 2003, Tesla's mission has been to accelerate the world's transition to sustainable energy," Tesla's website <a href="https://www.tesla.com/elon-musk">reads</a>.
Musk has said in the past that the acceleration of sustainable energy is fundamental to the future of humanity, as reported by <a href="https://www.cnbc.com/2019/02/04/elon-musk-on-the-why-and-purpose-behind-tesla.html#:~:text=We%20created%20Tesla%20to%20accelerate,for%20humanity%2C%22%20Musk%20said.">CNBC</a>.
These days, Musk and Tesla are focusing heavily on autonomous vehicles which could be the next political move by the Trump administration. Trump<a href="https://www.benzinga.com/general/politics/24/10/41298125/maybe-musk-missed-the-memo-trumps-plan-to-ban-autonomous-vehicles-could-sour-friendship"> previously said he </a>would ban autonomous vehicles from American roads.
Since then, Trump may have reversed his stance and come around to help boost the future of Musk's company by pushing autonomous vehicle testing forward and making Tesla's vision a reality.
Musk has watched his wealth soar <a href="https://www.benzinga.com/news/management/24/12/42444955/elon-musk-first-person-worth-400-billion-as-tesla-stock-hits-new-all-time-highs-how-2024-election-helped-could-lead-to-future-gains">to over $400 billion</a> since Trump won the 2024 presidential election.
While the new EV tax credit rules could be bad for the electric vehicle sector over time, the current president is likely going to be good for Musk and his company. The question is what the short and long-term impacts on Tesla will be. Based on the poll, investors don't seem too concerned about the potential loss of EV tax credits.
TSLA Price Action: Tesla stock closed down 0.57% to $424.07 on Tuesday versus a 52-week trading range of $138.80 to $488.54. Tesla stock is up 103% over the last year. Tesla's drop came while many stocks were up on the first trading day after Trump's inauguration with the SPDR S&amp;P 500 ETF up 0.92% to $603.05 Tuesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/01/42986863/us-electric-vehicle-sales-hit-record-1-3-million-units-in-2024-despite-tesla-declines-top-10-bestsel">US Electric Vehicle Sales Hit Record 1.3 Million Units In 2024, Despite Tesla Declines: Top 10 Bestselling Models</a></li>
</ul>
Photo: Courtesy Tesla

Politics

Trump's Plan To End $7,500 EV Tax Credits Could Be 'Devastating' For Telsa Rivals, Poll Says Could Be Bullish For Elon Musk's Company

Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) has outperformed the market over the past 20 years by 3.08% on an annualized basis producing an average annual return of 11.6%. Currently, Lockheed Martin has a market capitalization of $118.93 billion. 
Buying $100 In LMT: If an investor had bought $100 of LMT stock 20 years ago, it would be worth $897.68 today based on a price of $506.00 for LMT at the time of writing.
<h3>Lockheed Martin's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737500410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Lockheed Martin 20 Years Ago Would Be Worth This Much Today

This is subject to the completion of the Reverse Stock Split.

GSAT

Globalstar Intends To Voluntarily Delist From NYSE American And Transfer To Nasdaq

The data will be presented in a poster session (abstract #206) at the American Society of Clinical Oncology 2025 Gastrointestinal Cancer Symposium (ASCO GI) being held January 23-25, 2025, in San Francisco.
"We are very encouraged by the initial Phase 2 proof-of-concept data for the combination of vilastobart and atezolizumab in heavily pre-treated patients with MSS colorectal cancer, including partial responses accompanied by marked decreases in tumor biomarkers and improvement in clinical symptoms," said Katarina Luptakova, M.D., chief medical officer of Xilio.

Xilio Reports Initial Data From Ongoing Phase 2 Clinical Trial Evaluating Vilastobart In Combination With Atezolizumab; 27% Preliminary Response Rate Observed In Heavily Pre-Treated Microsatellite Stable Colorectal Cancer Patients Without Liver Metastases

The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is subject to market and other conditions and the completion of the SEC's review process.

IPOs

Voyager Technologies Submits Confidential Registration Statement For Proposed IPO

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 20 years by 19.56% on an annualized basis producing an average annual return of 28.09%. Currently, Intuitive Surgical has a market capitalization of $215.49 billion. 
Buying $100 In ISRG: If an investor had bought $100 of ISRG stock 20 years ago, it would be worth $13,941.23 today based on a price of $605.00 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737499516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ISRG

Here's How Much $100 Invested In Intuitive Surgical 20 Years Ago Would Be Worth Today

East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) has outperformed the market over the past 5 years by 3.68% on an annualized basis producing an average annual return of 16.95%. Currently, East West Bancorp has a market capitalization of $14.38 billion. 
Buying $1000 In EWBC: If an investor had bought $1000 of EWBC stock 5 years ago, it would be worth $2,106.64 today based on a price of $103.71 for EWBC at the time of writing.
<h3>East West Bancorp's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737498617_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EWBC

Here's How Much You Would Have Made Owning East West Bancorp Stock In The Last 5 Years

Contracts

GOOG

IAC Enters Further Amendment To Its Services Agreement With Google; Expiration Date Of Agreement Is Now March 31, 2026, With An Automatic Renewal For An Additional One-year Period - Filing

Roku Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) shares are trading higher in Tuesday&#8217;s after-hours session after Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) reported better-than-expected <a href="https://www.benzinga.com/25/01/43114866/netflix-q4-earnings-highlights-nfl-squid-game-power-best-subscriber-growth-in-company-history">financial results for the fourth quarter</a>.
What Happened With Netflix: Netflix reported fourth-quarter revenue of $10.25 billion, beating analysts estimates of $10.11 billion. The streaming giant reported quarterly earnings of $4.27 per share, beating analyst estimates of $4.19 per share.
Shares appear to be soaring in response to the company&#8217;s strong subscriber growth. Netflix said it added 18.91 million paid subscribers in the quarter, bringing its total subscriber count up to 301.63 million.
Netflix noted that its advertising plan continues to be quite popular, generating over 55% of sign-ups in the quarter. The company&#8217;s ads plan grew nearly 30% on a quarter-over-quarter basis.
&#8220;We're on track to reach sufficient scale for ads members in all of our ads countries in 2025. A top priority in 2025 is to improve our offering for advertisers so that we can substantially grow our advertising revenue,&#8221; the company said. 
NFLX Earnings: <a href="https://www.benzinga.com/25/01/43114866/netflix-q4-earnings-highlights-nfl-squid-game-power-best-subscriber-growth-in-company-history">Netflix Q4 Earnings: Record Subscribers, NFL, &#8216;Squid Game&#8217; Push Past &#8216;Highest Expectations&#8217;</a>
Why It Matters For ROKU: Roku is well-positioned to benefit from strong advertising trends from Netflix and other streaming companies.
Roku creates revenue opportunities with streaming companies through partnerships and advertising. The company operates an advertising distribution platform, allowing it to capitalize on the growth of streaming. Netflix was reportedly <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/06/27622300/3-reasons-why-this-analyst-thinks-a-netflix-roku-deal-may-not-materialize" target="_blank" rel="noreferrer noopener">considering a takeover of Roku</a> a couple of years ago, but a deal never materialized.
Roku is due to report its <a href="https://www.benzinga.com/calendars/earnings">fourth-quarter financial results</a> in early February, although a date has not yet been confirmed by the company. Analysts expect Roku to report a loss of 41 cents per share and revenue of $1.15 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
ROKU Price Action: <a href="http://benzinga.com/quote/roku">Roku shares</a> were up 3.71% in after-hours, trading at $82.70 at the time of publication Tuesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Entertainment

After-Hours Center

Media

NFLX

ROKU

Roku Stock Is Rising After-Hours Tuesday: Here's Why

As of January 17, 2025, a total of approximately 13.24 million shares remained available for repurchase under the existing repurchase authorization, resulting in an increase of 6.75 million shares of common stock available for repurchase.

Buybacks

HOMB

Home BancShares Increases Share Repurchase Program And Renew Authorization To 20M Shares

Results from Alpha-CORRECT, a study with one of the longest MRD surveillance monitoring periods to date, showed the Oncodetect test achieved 78% sensitivity at the post-surgical timepoint and 91% sensitivity during the surveillance monitoring period, with specificities of 80% and 94%, respectively.
Results from prospective molecular residual disease (MRD) study show a positive Oncodetect test result is strongly associated with recurrence in stage III colon cancer patients.
In addition to the data shared at ASCO GI, Oncodetect achieved its primary endpoint in the Beta-CORRECT study.&nbsp;
&nbsp;
&nbsp;

EXAS

Exact Sciences Says Oncodetect Test Achieved Primary Endpoint In Second Clinical Validation Study, Extending Prognostic Value Into Stages II And IV Colon Cancer And Rectal Cancer

Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) has outperformed the market over the past 15 years by 6.58% on an annualized basis producing an average annual return of 18.61%. Currently, Centene has a market capitalization of $32.14 billion. 
Buying $1000 In CNC: If an investor had bought $1000 of CNC stock 15 years ago, it would be worth $13,092.03 today based on a price of $63.66 for CNC at the time of writing.
<h3>Centene's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737497710_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Centene 15 Years Ago Would Be Worth This Much Today

Exact Sciences Plans To Present 11 Abstracts At ASCO GI Meeting In San Francisco

Efficacy was assessed in 10 of the 13 patients who received at least one dose of ozekibart, based on RECIST v1.1 criteria. Results demonstrated one complete response (CR), three partial responses (PR), and six cases of stable disease (SD). Durable disease control lasting ≥180 days was observed in 46.2% of patients, with a median progression-free survival (PFS) of 7.85 months.&nbsp;
Encouraged by these preliminary results, Inhibrx has initiated a new expansion cohort to validate these findings in a more uniform patient population. The cohort is expected to enroll up to 50 patients, each with two to three prior lines of systemic therapy, and data are anticipated in Q3 2025.

INBX

Inhibrx Reports Preliminary Efficacy And Safety Data From Phase 1 Trial Of Ozekibart (INBRX-109) For Treatment Of Colorectal Cancer; Initiates New Expansion Cohort To Validate Findings

ORLA

Orla Mining Says Shareholders Approved Acquisition Of Musselwhite Mine From Newmont

ING, PALI and FNCH among pre-market losers

Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers

CSSE, RVYL and RCAT among mid-day movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Finch Therapeutics Gr (NASDAQ:<a href="https://investorplace.com/stock-quotes/fnch-stock-quote/">FNCH</a>) just reported results for the first quarter of 2024.<ul><li>Finch Therapeutics Gr reported earnings per share of -$2.41.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/fnch-stock-earnings-finch-therapeutics-gr-for-q1-of-2024/">FNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

FNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q1 2024

Seth Klarman's Baupost cuts Warner Bros. stake, takes in SoundHound, among others

SCWorx, Cue Health, Sensei Biotherapeutics among healthcare movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Finch Therapeutics Gr (NASDAQ:<a href="https://investorplace.com/stock-quotes/fnch-stock-quote/">FNCH</a>) just reported results for the second quarter of 2024.<ul><li>Finch Therapeutics Gr reported earnings per share of -$3.01.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/fnch-stock-earnings-finch-therapeutics-gr-for-q2-of-2024/">FNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

FNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q2 2024

Comments

Finch Therapeutics Gr

Finch Therapeutics Gr (FNCH) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga